Controlled substances: research.

Legislative status

1. Introduced
2. In Committee
3. Reported by Committee
4. Floor Vote Scheduled
5. Passed One Chamber
6. Passed Both Chambers
7. Sent to Executive
8. Signed into Law

Summary

The bill lets California’s Research Advisory Panel submit investigational new drug applications to the FDA for clinical trials of Schedule I and II substances like psilocybin and ibogaine, focused exclusively on veterans with multiple severe mental health conditions. If the FDA does not act promptly, the panel can approve the studies itself, provided they meet peer‑review and IRB standards. It also updates the state controlled‑substances code to permit research use of these drugs and related mushroom spores.

AI-generated summary — may be incomplete or inaccurate. Verify against the official bill text.

Vote

From committee: Amend, and do pass as amended and re-refer to Com. on APPR. (Ayes 16. Noes 0.) (April 7). · Apr 8, 2026

Hearings

• Appropriations Committee Hearing
  Appropriations · May 14, 2026
• Appropriations Committee Hearing
  Appropriations · Apr 29, 2026
• Health Committee Hearing
  Health · Apr 7, 2026
• Health
  Health · Apr 7, 2026

History

1. May 14, 2026In committee: Held under submission.
2. May 14, 2026Coauthors revised.
3. Apr 29, 2026In committee: Set, first hearing. Referred to APPR. suspense file.
4. Apr 13, 2026Re-referred to Com. on APPR.
5. Apr 9, 2026Read second time and amended.
6. Apr 8, 2026From committee: Amend, and do pass as amended and re-refer to Com. on APPR. (Ayes 16. Noes 0.) (April 7).
7. Mar 9, 2026Referred to Coms. on HEALTH and M. & V.A.
8. Feb 21, 2026From printer. May be heard in committee March 23.
9. Feb 20, 2026Read first time. To print.

Sponsors

• Lowenthal · sponsor
• Harabedian
• Jeff Gonzalez
• Patterson

Bill text

Opens the legislature’s own copy.

Similar bills in other states

Loading the map of where bills like this one were filed.

Topics

Share